Healthy volunteers compare two methods of delivering navenibart

NCT ID NCT07635095

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial in 180 healthy adults compares two ways of giving the drug navenibart: by autoinjector or by vial and syringe. The goal is to see if both methods lead to similar drug levels in the blood and have similar safety. Participants receive one dose and are monitored in the clinic and during follow-up visits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

navenibart

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fortrea Clinical Trials

    RECRUITING

    Daytona Beach, Florida, 32117, United States

  • Fortrea Clinical Trials

    RECRUITING

    Dallas, Texas, 75247, United States

  • Fortrea Clinical Trials

    RECRUITING

    Madison, Wisconsin, 53704, United States